In patients with atrial fibrillation who were unable to receive warfarin for any reason, the use of apixaban reduced the risk of stroke and systemic embolism when compared to aspirin. Study Rundown: Atrial fibrillation is a common arrhythmia that increases the risk of stroke and. AVERROES has shown that the new oral anti-Xa inhibitor apixaban is superior to aspirin in terms of efficacy, with surprisingly similar safety. AVERROES. Apixaban Versus ASA. To Reduce the Risk Of Stroke. Coordinated by Population Health Research institute. Hamilton, Ontario, Canada. Sponsors.
|Published (Last):||2 December 2015|
|PDF File Size:||14.86 Mb|
|ePub File Size:||18.15 Mb|
|Price:||Free* [*Free Regsitration Required]|
All these reasons can be grouped in three broad categories: J Am Coll Averrofs ; Don’t miss out Read your latest personalised notifications Ok, got it. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation.
Sign in to My ESC. AVERROES on the other hand has shown that the new oral anti-Xa inhibitor apixaban is superior to aspirin in apxaban of efficacy, with surprisingly similar safety. ESC sub specialties communities. Yet, these proportions reflect the current underuse of VKAs in multiple registries. Apixaban in Patients with Atrial Fibrillation.
AVERROES – Wiki Journal Club
There were 51 primary outcome events in those randomised to apixaban 1. In addition, patients could not be receiving VKA therapy, either because it had been demonstrated unsuitable in their case or because it was expected to be unsuitable.
This page was last modified on 3 Decemberat Views Read View acerroes View history.
Read your latest personalised notifications Sign in No account yet? To reduce the burden of cardiovascular disease.
Adverse event not related to bleeding during VKA therapy; 3. Assessment that INR could not or was unlikely to be measured at requested interval; 5.
VKA therapy not recommended by the physician; Guidelines for the management of atrial fibrillation: Notes to editor Correspondence: Did you know that your browser is out of date? N Engl J Med ; Statistics presented where given by the authors. One may question each of these choices: It has multiple theoretical benefits over VKA therapy including less intensive monitoring and fewer drug interactions.
Navigation menu Avergoes tools Create account Log in. Thus, a clear superiority of apixaban over aspirin was shown in terms of efficacy, with comparable safety. Retrieved from ” http: Of the patients enrolled, reasons for being deemed unsuitable for VKA therapy included the following: There were 11 intracranial bleeds on apixaban and 13 on aspirin apixaban 1.
We will here briefly discuss the clinical implications of the trial. Connolly SJ, et al.
Assessment that patient would be unable or unlikely to adhere to restrictions on factors such as alcohol and diet; Eur Heart J ; In patients with atrial fibrillation thought to be unsuitable for anticoagulation with a vitamin K antagonist, does apixaban reduce risk for stroke or systemic embolism when compared to aspirin?
This proportion was similar for both academic and community hospitals. Based on the indirect comparison with ACTIVE A, one should conclude that apixaban is, at the time of writing, aveerroes best alternative to aspirin ever found in patients deemed unsuitable for VKAs. Patients were eligible if they were 50 years of age or older averroee if they had atrial fibrillation that had been documented averross the 6 months prior to enrollment or by lead electrocardiography on the day of screening.
The AVERROES Trial – Clinical Implications
Mortality rates were 3. Expected difficulty in contacting patient for urgent change in dose of VKAs; 6. In April the Data and Safety Monitoring Board recommended early study termination because of clear benefit in favor of apixaban. Dabigatran versus warfarin in patients with atrial fibrillation.
In such patients, avrroes plus clopidogrel reduced the rate of major vascular events, in particular stroke, vs.
The AVERROES Trial – Clinical Implications
With a mean follow-up of 1. A serious bleeding event during VKA therapy; 4. Patients also needed to have at least one of the following risk factors for stroke: The New England Journal of Medicine.